A bottle of medicine can finish its journey across the country and still be nowhere near the person who needs it. It may be sitting at a pharmacy, waiting for an insurer’s approval. Or the clinic may have the drug but need help managing the business around treatment. McKesson has spent nearly two centuries moving medicines. Its more recent investments follow the delays that remain after the truck arrives.
- Wholesale medicines provide the volume; services change the economics.
- Pharmacies, hospitals and biopharma companies buy the infrastructure.
- Oncology and community care are absorbing billions in new investment.
01 A very big number. A very small slice.
Start with $403.4 billion, McKesson’s revenue for the year ended March 31, 2026. That number describes a formidable flow of products and services. It does not describe how much money the company keeps. Expensive medicines pass through a distributor’s accounts, making revenue a particularly slippery measure of economic power.
The North American Pharmaceutical segment reported a 1.09% operating margin that year. Prescription Technology Solutions reported 17.98%. These are segment figures, before the full burden of corporate costs, interest and taxes. Still, the comparison explains why an enterprise associated with pallets and delivery schedules would be interested in software and patient access.
McKesson buys and distributes medicines, earning wholesale margins and service fees. Manufacturers gain a route to customers; pharmacies and hospitals gain supply without building the entire network themselves. Cencora and Cardinal Health are the familiar alternatives. McKesson’s pitch rests on the breadth of its connected businesses. Its rivals also combine distribution and services, so breadth alone does not settle the contest.
The expertise includes procurement, inventory planning and distribution technology. During the pandemic, McKesson served as the U.S. government’s centralized COVID-19 vaccine distributor. That assignment illustrates what a large delivery network can do when the customer needs coordination across many destinations, with handling requirements attached to the product.
02 Before the fax, there was the import ledger.
John McKesson and Charles Olcott opened a drug import and wholesale business in 1833. The original name put Olcott first. Over time, the business grew into a national distribution network. The underlying problem has remained recognizable: a maker and a medical customer need a dependable connection.
Modern customers need more than a delivery. Health Mart provides franchise support to thousands of independently owned pharmacies, including help with operations and marketing. A common name does not mean common ownership. For the pharmacist, the attraction is access to a larger support system while running a local business.
03 The prescription has another queue.
CoverMyMeds addresses a different kind of inventory problem: treatment that is prescribed but stalled. Its services connect pharmacies, prescribers, insurers and drugmakers around authorization, affordability and patient support. McKesson completed the acquisition in April 2017. The announced deal called for approximately $1.1 billion upfront, with up to $300 million in contingent consideration.
A box can be delivered while an approval remains unresolved. The practical value of the software is helping people work through that administrative gap. CoverMyMeds says it helped patients access medication more than 129 million times in 2025. That is a company-reported count of access events, not a count of unique patients or proof of clinical outcomes.
A box can be delivered while an approval remains unresolved.
04 Buying the work around cancer care.
The oncology expansion makes the strategy tangible. In June 2025, McKesson completed its purchase of roughly 70% of Core Ventures for about $2.49 billion. This was the business and administrative services organization established by Florida Cancer Specialists & Research Institute. FCS remained independently owned and joined The US Oncology Network.
The distinction matters. McKesson bought control of a services business supporting a medical practice. It did not announce that it had bought the physicians’ independent practice. The opportunity is to support the operations surrounding care while specialists continue treating patients.
Research extends that relationship. In 2022, McKesson and HCA Healthcare combined US Oncology Research and Sarah Cannon Research Institute in a joint venture. In August 2026, McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion, subject to approvals and closing conditions, adding proposed capabilities in clinical research and commercialization.
McKesson’s proposed investment for about 49% of Option Care Health, alongside CD&R. Expected closing: first half of 2027, subject to approvals.
Option Care supplies home and alternate-site infusion services. The proposed investment takes McKesson’s interests closer to where complex therapies are administered. The approximately $5.8 billion enterprise value belongs to the whole transaction; it is not McKesson’s proposed cash contribution.
05 The order that should have stopped.
Efficient movement has an uncomfortable counterpart: knowing when medicine should not move. In 2008, McKesson agreed to a $13.25 million penalty over suspicious controlled-substance reporting failures. A second settlement in 2017 imposed a $150 million civil penalty and enhanced compliance obligations.
The Justice Department said McKesson had designed a monitoring program after the earlier settlement but had not fully implemented or followed it. McKesson acknowledged failing to identify or report certain orders that should have appeared suspicious. The failure was in the controls around distribution. More throughput could not fix it; the settlement required oversight, auditing and an independent monitor.
Inside the company, the stated values are integrity, inclusion, customer-first, accountability, respect and excellence. Its onboarding program brings employees together with leaders and community-service projects. The monitoring history makes the standard for those values concrete: whether people follow the controls when an order is ready to leave.
06 Follow the next delay.
McKesson’s mission is to “Improve care in every setting.” Its portfolio choices suggest a more selective route toward that ambition: it completed its European exit in January 2026 and plans to separate Medical-Surgical Solutions while investing in specialty services.
The financial picture remains mixed. In the quarter ended June 2026, revenue rose 8% to $105.4 billion and adjusted earnings per share increased 20%. GAAP earnings per share fell. Growth in the selected measure should not obscure the difference; a reader needs both figures before drawing conclusions about performance.
The transferable idea is to study what still blocks your customer after your product arrives. That approach requires capital, integration skills and permission to work across organizational boundaries. It offers little help when the medicine is unavailable or coverage remains denied. McKesson’s next test is whether owning more of the surrounding work makes the patient’s journey measurably easier.